This revised news release replaces the one issued on

This revised news release replaces the one issued on November

14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's

request. The agreement with the new customer remains in effect.

Sensus Healthcare Reports Third Quarter

2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter

BOCA RATON, Fla, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare,

Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective

treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September

Highlights from the third quarter of 2024 and recent weeks include

Management Commentary

"Continued growth in revenues and earnings reflects our success

in engaging customers with both existing and new sales options. Our revenues more than doubled year-over-year for the second consecutive

quarter, and we maintained profitability despite the summer seasonality of our business," said Joe Sardano, chairman and chief executive

officer of Sensus Healthcare. "Our revenue-sharing Fair Deal Agreement, which allows customers to deploy capital elsewhere in their

businesses, continues to attract significant attention. Since our launch at the American Academy of Dermatology meeting in March, we signed

22 agreements as of September 30th."

Mr. Sardano added, "We have exceeded our goal of having up to

50 Fair Deal Agreements signed by the end of 2024, and we expect to be generating recurring revenue from these SRT-100 Vision (IG-SRT)

systems in 2025. Given the growing utilization of SRT to treat non-melanoma skin cancer and keloid scars, and the interest we have generated

to date, we expect this model to contribute to our growth for years to come. This model would not be possible without Sentinel IT, our

proprietary HIPAA-compliant software with clinical billing and asset management utility that also allows us to track utilization in real

time. We believe this intellectual property is a very valuable asset to Sensus."

Mr. Sardano concluded, "The market for non-melanoma skin cancer

treatments is enormous, with an estimated one in five Americans developing skin cancer during their lifetime, representing some 70 million

people. Globally, more than 1.2 million people develop non-melanoma skin cancer annually. Clearly SRT is becoming the people's

choice' on how they wish to be treated."

Third Quarter Financial Results

Revenues for the third quarter of 2024 were $8.8 million, compared

with $3.9 million for the third quarter of 2023, an increase of $4.9 million, or 127%. The increase was primarily driven by a higher number

of SRT systems sold to a large customer.

Cost of sales was $3.6 million for the third quarter of 2024, compared

with $1.9 million for the prior-year quarter. The increase was primarily related to a higher number of units sold in the 2024 quarter.

Gross profit was $5.2 million for the third quarter of 2024, or 59.3%

of revenues, compared with $2.0 million, or 51.0% of revenues, for the third quarter of 2023. The increase was primarily driven by the

higher number of units sold in the 2024 quarter.

Selling and marketing expense was $1.3 million for the third quarter

of 2024, unchanged from the third quarter of 2023.

General and administrative expense was $1.6 million for the third quarter

of 2024, compared with $1.5 million for the third quarter of 2023. The increase was primarily due to higher compensation and bad debt

expense, which were offset by a reduction in bank fees.

Research and development expense was $0.9 million for the third quarter

of 2024, compared with $1.1 million for the third quarter of 2023. The decrease was primarily due to expenses, mostly incurred in the

2023 quarter, related to a project to develop a drug delivery system for aesthetic use.

Other income of $0.3 million for the third quarter of 2024 was mostly

related to interest income, and was unchanged from the prior-year quarter.

Net income for the third quarter of 2024 was $1.2 million, or $0.07

per diluted share, compared with a net loss of $1.5 million, or $0.09 per share, for the third quarter of 2023.

Adjusted EBITDA for the third quarter of 2024 was $1.6 million, compared

with negative $1.7 million for the third quarter of 2023. Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before

interest, taxes, depreciation, amortization and stock-compensation expense. Please see below for a reconciliation between GAAP and non-GAAP

financial measures, and the reasons these non-GAAP financial measures are provided.

Cash and cash equivalents were $22.6 million as of September 30, 2024,

compared with $23.1 million as of December 31, 2023. The Company had no outstanding borrowings under its revolving line of credit. Accounts

receivable were $17.0 million as of September 30, 2024, compared with $10.6 million as of December 31, 2023, with the increase reflecting

the increase in sales and concentration of sales to a large customer that is subject to extended payment terms.

Nine Month Financial Results

Revenues for the nine months ended September 30, 2024 were $28.7 million,

compared with $11.8 million for the nine months ended September 30, 2023, an increase of $16.9 million, or 143%. The increase was primarily

driven by a higher number of units sold to a large customer.

Cost of sales was $11.4 million for the nine months ended September

30, 2024, compared with $5.6 million for the nine months ended September 30, 2023. The increase was primarily related to higher sales

Gross profit was $17.3 million, or 60.3% of revenues, for the nine

months ended September 30, 2024, compared with $6.2 million, or 52.6% of revenues, for the nine months ended September 30, 2023. The increase

was primarily driven by a higher number of units sold in the 2024 period.

Selling and marketing expense was $3.6 million for the nine months

ended September 30, 2024, compared with $5.0 million for the nine months ended September 30, 2023. The decrease was primarily attributable

to a decline in marketing agency expense, travel expense and lower headcount.

General and administrative expense was $4.7 million for the nine months

ended September 30, 2024, compared with $4.2 million for the nine months ended September 30, 2023. The increase was primarily due to higher

compensation and bad debt expense, which were offset by a reduction in bank fees and insurance expense.

Research and development expense was $2.7 million for the nine months

ended September 30, 2024, compared with $3.0 million for the nine months ended September 30, 2023. The decrease was primarily due to a

project to develop a drug delivery system for aesthetic use.

Other income of $0.7 million and $0.8 million for the nine months ended

September 30, 2024 and 2023, respectively, relates primarily to interest income.

Net income for the nine months ended September 30, 2024 was $5.1 million,

or $0.31 per diluted share, compared with a net loss of $3.7 million, or $0.23 per share, for the nine months ended September 30, 2023.

Adjusted EBITDA for the nine months ended September 30, was $6.7 million,

compared with negative $5.4 million for the nine months ended September 30, 2023.

Use of Non-GAAP Financial Information

This press release contains supplemental financial information determined

by methods other than in accordance with accounting principles generally accepted in the United States (GAAP). Sensus Healthcare management

uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis of the Company's performance. Adjusted EBITDA should not be

considered a substitute for GAAP basis measures, nor should it be viewed as a substitute for operating results determined in accordance

with GAAP. Management believes the presentation of Adjusted EBITDA, which excludes the impact of interest, income taxes, depreciation,

amortization and stock-compensation expense, provides useful supplemental information that is essential to a proper understanding of the

financial results of Sensus Healthcare. Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation

methods that differ from those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted

EBITDA assists investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that

may obscure underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in

GAAP TO NON-GAAP RECONCILIATION

Conference Call and Webcast

Sensus Healthcare held an investment community conference call on November

14, 2024 during which management discussed these financial results, provided a business update and answered questions.

A replay will be available until December 14, 2024 and can be accessed

by dialing 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International), using replay code 3932512.

An archived webcast of the call will also be available in the Investors section of the Company's website.

About Sensus Healthcare

Sensus Healthcare, Inc. is a global pioneer in the development and